2022
DOI: 10.1016/j.omtm.2022.03.003
|View full text |Cite
|
Sign up to set email alerts
|

A systematic comparison of optogenetic approaches to visual restoration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 16 publications
(18 citation statements)
references
References 84 publications
0
12
0
Order By: Relevance
“…Immunostaining of retina sections was performed as described previously (Gilhooley et al, 2022; Hughes et al, 2013). Visualization of ReaChR-mCitrine was enhanced using a chicken polyclonal anti-GFP antibody diluted 1:1000 that also recognizes mCitrine (GFP-1020, AVES labs).…”
Section: Methodsmentioning
confidence: 99%
“…Immunostaining of retina sections was performed as described previously (Gilhooley et al, 2022; Hughes et al, 2013). Visualization of ReaChR-mCitrine was enhanced using a chicken polyclonal anti-GFP antibody diluted 1:1000 that also recognizes mCitrine (GFP-1020, AVES labs).…”
Section: Methodsmentioning
confidence: 99%
“…A wider spectral range of neuronal activity modulators and voltage sensors together with improved optics will increase the scope for (all)-optical electrophysiological characterization of neural circuitry, also lending insight into neuronal function (and dysfunction) in the brain ( Villette et al, 2019 ; Guimarães Backhaus et al, 2021 ; Sharma et al, 2021 ; Zou et al, 2021 ; Prakash et al, 2022 ; Sridharan et al, 2022 ; Tan et al, 2022 ). Other important medical targets may also arise using optogenetics to correct physiological defects and address pathological conditions, where first steps have already been taken ( Braun et al, 1995 ; Deubner et al, 2019 ; Shen et al, 2020 ; Acharya et al, 2021 ; Cokic et al, 2021 ; Kathe et al, 2021 ; Gilhooley et al, 2022 ; Sun et al, 2022 ).…”
Section: Prospectsmentioning
confidence: 99%
“…An important issue is the extent to which we can expect functional benefits from bipolar-targeted versus downstream RCG-targeted therapy. Some studies have described the advantages of bipolar-targeted therapy [ 23 , 24 ], but the opposite result has also been reported [ 25 ]. Verification of the theoretical priority provided by preserving retinal processing would be the key to developing bipolar cell-targeted optogenetic therapy.…”
Section: Strategies and Target Cellsmentioning
confidence: 99%
“…Tyrosine-mutated AAVs are generated through rational mutagenesis to improve intracellular nuclear trafficking, based on the finding that phosphorylation of surface-exposed tyrosine residues on AAV leads to ubiquitination and subsequent proteasome-mediated degradation. Intravitreal injection of AAV2 quadruple mutants (Y272, 444, 500, 730F; 4YF) has been demonstrated to transduce bipolar cells using either the Grm6 [ 16 , 20 , 72 ] or L7-5 promoter [ 24 , 51 ] in rodent models. When AAV2(4YF) was used with the hSyn-1 promoter, optogenetic gene expression was dominant in RGCs [ 70 ].…”
Section: Gene Deliverymentioning
confidence: 99%